Guangzhou Boji Medical Biotechnological Co., Ltd, a Clinical Research Organization (CRO) based in China and listed on the Shenzhen Stock Exchange (SHE: 300404), has entered into a strategic partnership with its wholly-owned Traditional Chinese Medicine (TCM) subsidiary and CapitalBio Pharma, a domestic firm, to collaborate on the research and development of innovative TCM products. The financial specifics of the agreement have not been disclosed.
In the preceding month, a joint venture (JV) was established between CapitalBio and Shanghai Tingden Information Technology Co., Ltd, with a registered capital of RMB 5 million. CapitalBio is dedicated to equipping the JV with its specialized vertical models in TCM and the application capabilities of molecular herbal databases, thereby enhancing the JV’s preclinical research and innovation capabilities in TCM. Boji will utilize its advanced clinical expertise in TCM to offer services for the JV’s innovative projects, creating a comprehensive innovation chain loop for TCM.
The partners intend to identify existing research projects with commercial potential and establish a rapid screening platform for TCM prescriptions. This platform will employ a large TCM model combined with human experience to efficiently and accurately screen numerous existing hospital or folk prescriptions, with the goal of commercializing the most promising ones. Both parties aim to continuously refine and upgrade the infrastructure of the TCM innovation model at the JV level.
In addition to TCM, the JV is set to explore other opportunities in the broader health industry, including but not limited to specialty foods, health products, medical aesthetics, and personalized testing within the burgeoning big health market.- Flcube.com